Designed and Engineered with a heart.
Made with compassion.
Hitaa bv works with a diverse, international multidisciplinary team of experts from design, engineering and healthcare fields in a partnership with end users, healthcare professionals, people with lived and living experience.
Hitaa bv co-creates, designs, engineers, develops, and manufactures medical devices with innovative affordable technology solutions for the people of the world, to reduce inequity.
Hitaa bv works with a diverse, international multidisciplinary team of experts from design, engineering and healthcare fields in a partnership with end users, healthcare professionals, people with lived and living experience.
Hitaa bv co-creates, designs, engineers, develops, and manufactures medical devices with innovative affordable technology solutions for the people of the world, to reduce inequity.
A diverse, international multidisciplinary team of experts from design, engineering and healthcare fields envision to co-create, design, develop, manufacture and market a novel inhaler.
“This novel inhaler has a potential
to be a game changer.”
– Dr. Don Cockroft
World-renowned respirologist, University of Saskatchewan, Canada
“The Hitaa Med-Tech start-up initiative, involving key experts in the field, will create a unique collaboration between SME’s, researchers and community participants. Dutch pulmonologists are pleased to participate as a Knowledge User for the ‘Novel Inhaler is a Reusable, and Long-lasting Inhaler’.”
– Dr. Els JM Weersink
Department of Respiratory Diseases, Amsterdam UMC, The Netherlands, Board member SAB and RAPSODI, Member NRS and Longfonds, The Netherlands
“The novel inhaler would be a game changer in not only providing affordable care in the treatment of respiratory diseases but also aiding in the combat against climate change by providing a reusable inhaler and in turn reducing plastic and chemical pollution. There is an urgent need to develop a cost-friendly inhaler product to provide equitable care for vulnerable populations and address the shortages of inhalers exacerbated by the COVID-19 pandemic.”
